Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ibrutinib works in treating patients with B-cell acute
lymphoblastic leukemia that has come back after treatment or has not responded to other
treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.